Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation
Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).
A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study.
An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib arm.
Enhanced effects for both PVR and 6MWD were observed in patients with more severe baseline disease.
Related: Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial.
In FC III patients, a 21% reduction in PVR and 37m improvement in 6MWD were observed for the seralutinib arm vs. placebo.
Seralutinib treatment resulted in a statistically significant reduction in NT-proBNP, a biomarker of right heart stress, as early as 12 weeks, increasing to a 408.3 ng/L mean difference from placebo at Week 24.
Seralutinib was generally well tolerated in the TORREY study, with treatment-emergent adverse events (TEAEs) reported in 36 (86%) and 41 (93%) of the patients in the placebo and seralutinib arms, respectively.
Price Action: GOSS shares are down 67.70% at $3.00 on the last check Tuesday.
See more from Benzinga
Summit Therapeutics Shares Surge After Licensing Agreement For Cancer Program
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.